Compile Data Set for Download or QSAR
Found 173 with Last Name = 'knolle' and Initial = 'j'
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Hoechst AG

Curated by ChEMBL
LigandPNGBDBM50050776((S)-3-{2-[(S)-4-(4-Carbamimidoyl-phenyl)-4-methyl-...)copy SMILEScopy InChI
Affinity DataKi:  0.170nMAssay Description:Inhibition of [125I]-fibrinogen binding to isolated GPIIb/IIIaMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2KW5F4XPubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Hoechst AG

Curated by ChEMBL
LigandPNGBDBM50050776((S)-3-{2-[(S)-4-(4-Carbamimidoyl-phenyl)-4-methyl-...)copy SMILEScopy InChI
Affinity DataKi:  9nMAssay Description:Inhibition of [125I]-fibrinogen binding to ADP-activated human gel filtered plateletsMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2KW5F4XPubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101753((S)-2-(4-Isopropyl-benzenesulfonylamino)-3-({5-[2-...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101763((S)-2-(3-Chloro-propane-1-sulfonylamino)-3-({5-[2-...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101759((S)-2-(4-Chloro-benzenesulfonylamino)-3-({5-[2-(1,...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101766((S)-2-Ethenesulfonylamino-3-({5-[2-(1,4,5,6-tetrah...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101761((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101768((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101773((S)-2-(Naphthalene-1-sulfonylamino)-3-({5-[2-(1,4,...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101755((S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-{[5-(...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101769((S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-({5-[2...)copy SMILEScopy InChI
Affinity DataIC50: 3nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101770((S)-2-(Biphenyl-4-sulfonylamino)-3-({5-[2-(1,4,5,6...)copy SMILEScopy InChI
Affinity DataIC50: 3nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101779((S)-2-(Quinoline-8-sulfonylamino)-3-({5-[2-(1,4,5,...)copy SMILEScopy InChI
Affinity DataIC50: 3nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101764((S)-2-(Butane-1-sulfonylamino)-3-({5-[2-(1,4,5,6-t...)copy SMILEScopy InChI
Affinity DataIC50: 4nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101772((S)-2-Chloromethanesulfonylamino-3-({5-[2-(1,4,5,6...)copy SMILEScopy InChI
Affinity DataIC50: 4nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101771((S)-2-(Propane-1-sulfonylamino)-3-({5-[2-(1,4,5,6-...)copy SMILEScopy InChI
Affinity DataIC50: 4nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101751((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)copy SMILEScopy InChI
Affinity DataIC50: 5nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101754((S)-2-Methanesulfonylamino-3-({5-[2-(1,4,5,6-tetra...)copy SMILEScopy InChI
Affinity DataIC50: 5nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101753((S)-2-(4-Isopropyl-benzenesulfonylamino)-3-({5-[2-...)copy SMILEScopy InChI
Affinity DataIC50: 6nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101768((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)copy SMILEScopy InChI
Affinity DataIC50: 7nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101765((2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(5-{2-[(1,4...)copy SMILEScopy InChI
Affinity DataIC50: 7nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101767(3-Benzo[1,3]dioxol-5-yl-3-{[5-((E)-3-guanidino-3-o...)copy SMILEScopy InChI
Affinity DataIC50: 8nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50403867(CHEMBL2115098)copy SMILEScopy InChI
Affinity DataIC50: 9nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Hoechst AG

Curated by ChEMBL
LigandPNGBDBM50101770((S)-2-(Biphenyl-4-sulfonylamino)-3-({5-[2-(1,4,5,6...)copy SMILEScopy InChI
Affinity DataIC50: 9nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101761((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)copy SMILEScopy InChI
Affinity DataIC50: 10nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101752(3-Benzo[1,3]dioxol-5-yl-3-{[5-(3-guanidino-3-oxo-p...)copy SMILEScopy InChI
Affinity DataIC50: 10nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101760((S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-{[5-(...)copy SMILEScopy InChI
Affinity DataIC50: 10nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Hoechst AG

Curated by ChEMBL
LigandPNGBDBM50101761((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)copy SMILEScopy InChI
Affinity DataIC50: 11nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101759((S)-2-(4-Chloro-benzenesulfonylamino)-3-({5-[2-(1,...)copy SMILEScopy InChI
Affinity DataIC50: 12nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101769((S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-({5-[2...)copy SMILEScopy InChI
Affinity DataIC50: 12nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101773((S)-2-(Naphthalene-1-sulfonylamino)-3-({5-[2-(1,4,...)copy SMILEScopy InChI
Affinity DataIC50: 13nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101758(3-Benzo[1,3]dioxol-5-yl-3-{[5-(2-guanidinocarbonyl...)copy SMILEScopy InChI
Affinity DataIC50: 16nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Hoechst AG

Curated by ChEMBL
LigandPNGBDBM50101753((S)-2-(4-Isopropyl-benzenesulfonylamino)-3-({5-[2-...)copy SMILEScopy InChI
Affinity DataIC50: 17nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Hoechst AG

Curated by ChEMBL
LigandPNGBDBM50101763((S)-2-(3-Chloro-propane-1-sulfonylamino)-3-({5-[2-...)copy SMILEScopy InChI
Affinity DataIC50: 17nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Jerini AG

Curated by ChEMBL
LigandPNGBDBM50192056(Ac-Phe-[Orn-Pro-cha-Trp-Nva] | CHEMBL412031)copy SMILEScopy InChI
Affinity DataIC50: 18nMAssay Description:Antagonist activity at human C5aR in CD88 transfected RBL cells assessed as inhibition of C5a-induced glucosaminidase releaseMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2RX9BP8PubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Jerini AG

Curated by ChEMBL
LigandPNGBDBM50192070(Ac-Phe-[Orn-Pro-cha-Trp-Orn] | CHEMBL405647)copy SMILEScopy InChI
Affinity DataIC50: 18nMAssay Description:Antagonist activity at human C5aR in CD88 transfected RBL cells assessed as inhibition of C5a-induced glucosaminidase releaseMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2RX9BP8PubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Jerini AG

Curated by ChEMBL
LigandPNGBDBM50192059(Ac-Ala-[Orn-Pro-cha-Trp-Eag] | CHEMBL214024)copy SMILEScopy InChI
Affinity DataIC50: 19nMAssay Description:Antagonist activity at human C5aR in CD88 transfected RBL cells assessed as inhibition of C5a-induced glucosaminidase releaseMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2RX9BP8PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50085011(2-Benzyloxycarbonylamino-3-(2-{(S)-4-[3-(4,5-dihyd...)copy SMILEScopy InChI
Affinity DataIC50: 20nMAssay Description:Inhibition of Kistrin binding to integrin alphaV-beta3More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q290249VPubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Jerini AG

Curated by ChEMBL
LigandPNGBDBM50192043(Ac-Phe-[Orn-Pro-cha-Trp-Thi] | CHEMBL425469)copy SMILEScopy InChI
Affinity DataIC50: 22nMAssay Description:Antagonist activity at human C5aR in CD88 transfected RBL cells assessed as inhibition of C5a-induced glucosaminidase releaseMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2RX9BP8PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101771((S)-2-(Propane-1-sulfonylamino)-3-({5-[2-(1,4,5,6-...)copy SMILEScopy InChI
Affinity DataIC50: 22nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Jerini AG

Curated by ChEMBL
LigandPNGBDBM50192051(Ac-Phe-[Orn-Pro-cha-Trp-Nle] | CHEMBL374575)copy SMILEScopy InChI
Affinity DataIC50: 25nMAssay Description:Antagonist activity at human C5aR in CD88 transfected RBL cells assessed as inhibition of C5a-induced glucosaminidase releaseMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2RX9BP8PubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Jerini AG

Curated by ChEMBL
LigandPNGBDBM50192061(Ac-Phe-[Orn-Ala-cha-Trp-Arg] | CHEMBL405646)copy SMILEScopy InChI
Affinity DataIC50: 25nMAssay Description:Antagonist activity at human C5aR in CD88 transfected RBL cells assessed as inhibition of C5a-induced glucosaminidase releaseMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2RX9BP8PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101770((S)-2-(Biphenyl-4-sulfonylamino)-3-({5-[2-(1,4,5,6...)copy SMILEScopy InChI
Affinity DataIC50: 26nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Jerini AG

Curated by ChEMBL
LigandPNGBDBM50192062(Ac-Phe-[Orn-Pro-cha-Trp-Phe] | CHEMBL375443)copy SMILEScopy InChI
Affinity DataIC50: 26nMAssay Description:Antagonist activity at human C5aR in CD88 transfected RBL cells assessed as inhibition of C5a-induced glucosaminidase releaseMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2RX9BP8PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101755((S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-{[5-(...)copy SMILEScopy InChI
Affinity DataIC50: 26nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Jerini AG

Curated by ChEMBL
LigandPNGBDBM50192044(Ac-Phe-Orn-Pro-hle-Bta-Phe-NH2 | CHEMBL262177)copy SMILEScopy InChI
Affinity DataIC50: 27nMAssay Description:Antagonist activity at human C5aR in CD88 transfected RBL cells assessed as inhibition of C5a-induced glucosaminidase releaseMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2RX9BP8PubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Jerini AG

Curated by ChEMBL
LigandPNGBDBM50111445((S)-N-((3R,6S,9S,15S,20aS)-6-((1H-indol-3-yl)methy...)copy SMILEScopy InChI
Affinity DataIC50: 29nMAssay Description:Antagonist activity at human C5aR in CD88 transfected RBL cells assessed as inhibition of C5a-induced glucosaminidase releaseMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2RX9BP8PubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Jerini AG

Curated by ChEMBL
LigandPNGBDBM50192057(Ac-Phe-Orn-Pro-cha-Trp-Phe-NH2 | CHEMBL376905)copy SMILEScopy InChI
Affinity DataIC50: 31nMAssay Description:Antagonist activity at human C5aR in CD88 transfected RBL cells assessed as inhibition of C5a-induced glucosaminidase releaseMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2RX9BP8PubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Jerini AG

Curated by ChEMBL
LigandPNGBDBM50111445((S)-N-((3R,6S,9S,15S,20aS)-6-((1H-indol-3-yl)methy...)copy SMILEScopy InChI
Affinity DataIC50: 31nMAssay Description:Antagonist activity at human C5aR expressed in human PMN cells assessed as inhibition of glucosaminidase releaseMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2RX9BP8PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101776(3-Benzo[1,3]dioxol-5-yl-3-({5-[(E)-2-(1,4,5,6-tetr...)copy SMILEScopy InChI
Affinity DataIC50: 32nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
Displayed 1 to 50 (of 173 total ) | Next | Last >>
Jump to: